Windtree Therapeutics, Inc. - Special Call Transcript
Good morning. Welcome to the Windtree and lifesci sponsored KOL morning breakfast. I appreciate all of you being here, particularly on a rainy -- a very rainy day in New York. Wish we could have the weather from this weekend and -- carried over through the rest of the week. But -- and for everybody who is on the webcast and joining us, welcome to all of you globally, in fact. So we have a lot going on right now with regard to our programs and our development. And I just wanted to take a quick moment to introduce you to what is, in many ways, a new company and a new outlook, although the company, Windtree, has been around for a few years. We are coming off of, for us, a major acquisition and off -- coming off of some M&A activity that closed last year out. And as we come into this year, we are now a post-merger global acute care company focused in acute pulmonary and acute cardiovasculars. We're a public company on the OTC board, and we are a small-cap company of about $150 million market cap. I think we've been under the radar
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |